↓ Skip to main content

Zika vaccines and therapeutics: landscape analysis and challenges ahead

Overview of attention for article published in BMC Medicine, June 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)

Mentioned by

news
2 news outlets
twitter
9 tweeters

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
124 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Zika vaccines and therapeutics: landscape analysis and challenges ahead
Published in
BMC Medicine, June 2018
DOI 10.1186/s12916-018-1067-x
Pubmed ID
Authors

Annelies Wilder-Smith, Kirsten Vannice, Anna Durbin, Joachim Hombach, Stephen J. Thomas, Irani Thevarjan, Cameron P. Simmons

Abstract

Various Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and effective ZIKV vaccines. Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome. Establishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate efficacy. Continued financial support and engagement of industry partners will be essential to the successful development, licensure, and accessibility of Zika vaccines or therapeutics.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 124 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 29 23%
Student > Bachelor 20 16%
Researcher 18 15%
Student > Ph. D. Student 14 11%
Student > Doctoral Student 7 6%
Other 11 9%
Unknown 25 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 22 18%
Medicine and Dentistry 18 15%
Immunology and Microbiology 14 11%
Agricultural and Biological Sciences 9 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 19 15%
Unknown 36 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2021.
All research outputs
#1,413,559
of 18,812,670 outputs
Outputs from BMC Medicine
#1,026
of 2,818 outputs
Outputs of similar age
#35,895
of 291,449 outputs
Outputs of similar age from BMC Medicine
#1
of 1 outputs
Altmetric has tracked 18,812,670 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,818 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.5. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,449 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them